PL295403A1 - - Google Patents

Info

Publication number
PL295403A1
PL295403A1 PL92295403A PL29540392A PL295403A1 PL 295403 A1 PL295403 A1 PL 295403A1 PL 92295403 A PL92295403 A PL 92295403A PL 29540392 A PL29540392 A PL 29540392A PL 295403 A1 PL295403 A1 PL 295403A1
Authority
PL
Poland
Prior art keywords
thiomorpholino
thiazolidinyl
azetidinyl
alzheimer
dioxide
Prior art date
Application number
PL92295403A
Other languages
English (en)
Other versions
PL169247B1 (pl
Inventor
Keulen Berend Jan Van
Solo Goldstein
Eric Cossement
Jean Gobert
Ernst Wuelfert
Original Assignee
Ucb Departement D T B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Departement D T B filed Critical Ucb Departement D T B
Publication of PL295403A1 publication Critical patent/PL295403A1/xx
Publication of PL169247B1 publication Critical patent/PL169247B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Epoxy Resins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL92295403A 1991-07-25 1992-07-24 Sposób wytwarzania nowych pochodnych cyklopropyloamino-1,3,5-triazyny PL PL PL PL PL PL PL PL PL PL169247B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919116039A GB9116039D0 (en) 1991-07-25 1991-07-25 Substituted cyclopropylamino-1,3,5-triazines

Publications (2)

Publication Number Publication Date
PL295403A1 true PL295403A1 (pl) 1993-02-08
PL169247B1 PL169247B1 (pl) 1996-06-28

Family

ID=10698941

Family Applications (2)

Application Number Title Priority Date Filing Date
PL92295403A PL169247B1 (pl) 1991-07-25 1992-07-24 Sposób wytwarzania nowych pochodnych cyklopropyloamino-1,3,5-triazyny PL PL PL PL PL PL PL PL PL
PL92311241A PL169646B1 (pl) 1991-07-25 1992-07-24 Sposób wytwarzania nowych pochodnych cykIopropyloamino-1,3,5-triazyny PL PL PL PL PL PL PL PL PL

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL92311241A PL169646B1 (pl) 1991-07-25 1992-07-24 Sposób wytwarzania nowych pochodnych cykIopropyloamino-1,3,5-triazyny PL PL PL PL PL PL PL PL PL

Country Status (21)

Country Link
US (2) US5258513A (pl)
EP (1) EP0527117B1 (pl)
JP (1) JP3138540B2 (pl)
KR (1) KR100221400B1 (pl)
AT (1) ATE159719T1 (pl)
AU (1) AU648424B2 (pl)
CA (1) CA2072680A1 (pl)
DE (1) DE69222903T2 (pl)
DK (1) DK0527117T3 (pl)
ES (1) ES2109332T3 (pl)
FI (1) FI923314L (pl)
GB (1) GB9116039D0 (pl)
GR (1) GR3026017T3 (pl)
HU (1) HU218207B (pl)
IE (1) IE922422A1 (pl)
NO (1) NO300683B1 (pl)
NZ (1) NZ243681A (pl)
PL (2) PL169247B1 (pl)
RU (1) RU2095353C1 (pl)
UA (1) UA27749C2 (pl)
ZA (1) ZA924920B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US6400819B1 (en) * 1996-03-28 2002-06-04 Hitachi, Ltd. Method and apparatus for executing communication in real-time and data structure for real-time data communication
WO1998011076A1 (de) * 1996-09-13 1998-03-19 Lonza Ag Verfahren zur herstellung von 6-methyl-2-methylamino-4-methoxy-1,3,5-triazin
US6538750B1 (en) 1998-05-22 2003-03-25 Cyberoptics Corporation Rotary sensor system with a single detector
US6292261B1 (en) 1998-05-22 2001-09-18 Cyberoptics Corporation Rotary sensor system with at least two detectors
FI105684B (fi) * 1998-08-21 2000-09-29 Neste Chemicals Oy Enantioselektiiviset kiraaliset sulfidikatalyytit, menetelmä niiden valmistamiseksi ja niiden käyttö stereoselektiivisiin epoksidointi-, syklopropanointi- ja atsiridinointireaktioihin
EP1185528A4 (en) * 1999-06-17 2003-03-26 Shionogi Biores Corp INHIBITORS OF IL-12 PRODUCTION
US6384032B1 (en) * 1999-06-17 2002-05-07 Shionogi Bioresearch Corp. Inhibitors of IL-12 production
PL200923B1 (pl) 1999-08-21 2009-02-27 Nycomed Gmbh Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu
CN1098876C (zh) * 1999-09-21 2003-01-15 上海赛璐化工股份有限公司 一种长碳链共聚酰胺及其制备方法
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6680315B2 (en) * 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
BR0214809A (pt) * 2001-11-30 2004-09-14 Synta Pharmaceuticals Corp Compostos de pirimidina
RU2234500C1 (ru) * 2002-11-15 2004-08-20 Кубанский государственный аграрный университет Способ получения простых макроэфиров сим-триазинового ряда
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
JP4851337B2 (ja) * 2003-11-10 2012-01-11 シンタ ファーマシューティカルズ コーポレーション ヘテロアリールヒドラゾン化合物
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
EP2742020B1 (en) * 2011-08-08 2017-10-25 Immunomet Therapeutics Inc. N1-cyclic amine-n5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
CA2920856C (en) 2013-08-09 2026-03-03 Ardelyx, Inc. Ph modulating compounds for inhibiting gastrointestinal phosphate uptake
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス, インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160831A (en) * 1976-08-19 1979-07-10 Ciba-Geigy Corporation Novel insecticides
EP0003749B1 (de) * 1978-02-03 1982-09-15 Ciba-Geigy Ag 2-Methylthio-4-cyclopropylamino-6-(Alpha,Beta-dimethylpropylamino)-s-triazin und die Verwendung von Triazinderivaten als Meerwasseralgizide
GB8819494D0 (en) * 1988-08-16 1988-09-21 Ucb Sa Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments
GB8819493D0 (en) * 1988-08-16 1988-09-21 Ucb Sa 2-amino-4-morpholino-6-propyl-1 3 5-triazines

Also Published As

Publication number Publication date
ZA924920B (en) 1993-04-28
NO300683B1 (no) 1997-07-07
JPH06220026A (ja) 1994-08-09
US5258513A (en) 1993-11-02
GR3026017T3 (en) 1998-04-30
NO922922D0 (no) 1992-07-23
US5348956A (en) 1994-09-20
HUT66218A (en) 1994-10-28
KR930002327A (ko) 1993-02-23
UA27749C2 (uk) 2000-10-16
AU648424B2 (en) 1994-04-21
CA2072680A1 (en) 1993-01-26
DE69222903D1 (de) 1997-12-04
FI923314A0 (fi) 1992-07-21
PL169646B1 (pl) 1996-08-30
JP3138540B2 (ja) 2001-02-26
RU2095353C1 (ru) 1997-11-10
AU2053492A (en) 1993-01-28
DK0527117T3 (da) 1998-05-18
ATE159719T1 (de) 1997-11-15
KR100221400B1 (ko) 1999-09-15
IE922422A1 (en) 1993-01-27
PL169247B1 (pl) 1996-06-28
EP0527117B1 (fr) 1997-10-29
FI923314A7 (fi) 1993-01-26
EP0527117A1 (fr) 1993-02-10
DE69222903T2 (de) 1998-03-26
GB9116039D0 (en) 1991-09-11
HU9202441D0 (en) 1992-10-28
NZ243681A (en) 1997-06-24
FI923314L (fi) 1993-01-26
NO922922L (no) 1993-01-26
HU218207B (hu) 2000-06-28
ES2109332T3 (es) 1998-01-16

Similar Documents

Publication Publication Date Title
ZA924920B (en) Substituted cyclopropylamino-1,3,5-triazines
IL87834A0 (en) Novel oxathiolanes
HUT60735A (en) Process for producing piperidyloxy and quinuclidinyloxy isoxazole derivatives and pharmaceutical compositions comprising such compounds
GR3034023T3 (en) Phenyl carboxamide-isoxazole-derivatives and salts, process for their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.
AU633791B2 (en) 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
IN167549B (pl)
ZA927279B (en) Imidazolylmethyl-pyridines
IL98914A0 (en) Process for the preparation of 6-(substituted aminopropionyl)derivatives of forskolin
IL107001A0 (en) Tetrahydroacridine amino compounds and pharmaceutical compositions containing them
CA2296901A1 (en) Piperidine derivates having anxiolytic effect
ATE133953T1 (de) Hexahydro-1h-chino(4,3,2-ef>(1,4>benzoxazepine und verwandte verbindungen und zwischenprodukte zur herstellung und verwendung als arzneimittel
GR3018068T3 (en) Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs.